Standout Papers

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomi... 2021 2026 2022 2024131
  1. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial (2021)
    Satoshi Ebata, Ayumi Yoshizaki et al. The Lancet Rheumatology

Immediate Impact

6 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
2024 Standout
Interstitial Lung Disease
2024 Standout
1 intermediate paper

Works of Keiko Ueda being referenced

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Keiko Ueda 237 171 206 301 288 59 1.2k
Günter Stein 124 92 208 496 306 66 1.7k
Kai Lau 249 231 205 180 594 46 1.6k
Neil Dalton 215 75 273 231 262 53 1.3k
Michaele B. Manigrasso 175 252 184 287 426 33 1.7k
Mika Enomoto 127 265 349 226 194 54 1.4k
Jacques Bernheim 258 105 210 109 200 60 1.4k
Alev Hasanoğlu 83 144 314 170 240 88 1.2k
Takuhito Shoji 85 225 198 549 206 39 1.4k
Dariusz Moczulski 49 133 210 155 280 65 1.4k
Necat Yılmaz 60 88 149 150 231 83 1.2k

All Works

Loading papers...

Rankless by CCL
2026